Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05926336 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | unknown | Phase 4 | 1,316 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 28, 2023 |
| clinicaltrials |
| NCT01706120 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab(MITO16/MANGO-2) | unknown | Phase 4 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer(POLO) | unknown | Phase 4 | 102 | Seoul National University HospitalOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT03349463 | Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | unknown | Phase 4 | 30 | Bital Savir-BaruchOTHER | 1 | Feb 28, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Nov 29, 2023source: clinicaltrials